The Clinical Evidence Behind Semaglutide

Mechanism of action — Dual incretin receptor agonism

Semaglutide is the first GLP-1 receptor agonist approved for clinical use. The two incretins activated by semaglutide function complementarily:

• GLP-1 (glucagon-like peptide-1): Secreted by intestinal L-cells. Reduces appetite via central nervous system signaling, delays gastric emptying, increases glucose-dependent insulin secretion, suppresses glucagon.
• GIP (glucose-dependent insulinotropic polypeptide): Secreted by intestinal K-cells. Synergistic effects on insulin secretion, additional preferential effects on adipose tissue insulin sensitivity, modest contributions to energy expenditure.

The receptor agonism explains the magnitude of weight loss observed with semaglutide vs single-receptor GLP-1 agonists like semaglutide.

STEP trial program — Semaglutide for chronic weight management

STEP-1 (Pivotal weight loss trial in adults without diabetes)

Wilding JP, et al., New England Journal of Medicine, 2021. n=1,961 adults with BMI ≥30 (or ≥27 with weight-related comorbidity), without type 2 diabetes. 68-week trial. Primary outcome: -14.9% mean change in body weight on semaglutide 2.4 mg vs -2.4% on placebo. Proportion achieving ≥5% / ≥10% / ≥15% weight loss: 86.4% / 69.1% / 50.5% on semaglutide vs 31.5% / 12.0% / 4.9% on placebo. Both arms received lifestyle intervention. PMID: 33567185.

STEP-2 (Semaglutide in T2 diabetes)

Garvey WT, et al., Lancet 2023. n=938 adults with T2D and obesity. Confirmed efficacy in patients with diabetes.

STEP-3 (With intensive lifestyle intervention)

Wadden TA, et al., Nat Med 2023. Semaglutide combined with intensive behavioral therapy. Demonstrated additive effect.

STEP-4 (Maintenance after initial weight loss)

Aronne LJ, et al., JAMA 2024. Semaglutide continuation vs withdrawal. Sustained weight maintenance with continued therapy and significant weight regain with withdrawal.

SUSTAIN trial program — Semaglutide for T2 diabetes

SUSTAIN-2 (Head-to-head with semaglutide)

Frías JP, et al., NEJM 2021. n=1,879 adults with T2D. Semaglutide demonstrated superior glycemic control AND ~47% greater weight loss at all doses vs semaglutide. PMID: 34170647.

SOUL (Cardiovascular outcomes — in progress)

Ongoing trial evaluating semaglutide cardiovascular outcomes vs dulaglutide in patients with T2D and established CV disease. Results expected 2026-2027.

Compounded semaglutide — pharmacy quality standards

• USP <797> — sterile compounding standards including environmental controls, personnel training, beyond-use dating
• USP <71> — sterility testing
• USP <85> — bacterial endotoxin testing
• FDA cGMP (21 CFR 211) — applies to 503B outsourcing facilities

NexLife discloses adherence to all the above; many competitors do not.

Side effect profile

Most common adverse events from STEP-1 and SUSTAIN trials:

• Nausea — 25-31%
• Diarrhea — 19-23%
• Decreased appetite — 9-11%
• Vomiting — 8-12%
• Constipation — 6-10%

Boxed warnings & contraindications

Semaglutide carries a boxed warning regarding the risk of thyroid C-cell tumors (rodent studies). Contraindicated in:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy and breastfeeding
• Severe gastroparesis (use with caution)
• History of pancreatitis (use with caution)

For deeper clinical resources, see clinical research index.